Vaccinex, Inc. operates as a clinical-stage biotechnology company. It engages in the development of targeted bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses on the development of Pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma, and Huntington’s disease. Its product pipeline includes the SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer in1997 and is headquartered in Rochester, NY.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Vaccinex Inc market cap is $2.41M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Vaccinex Inc 52 week high is $1.50 as of November 20, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Vaccinex Inc 52 week low is $0.31 as of November 20, 2026.
Vaccinex Inc stock price today is $0.9743.
Vaccinex Inc stock price yesterday was $0.90.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Vaccinex Inc 50-day moving average is $0.9545.